Adaptive Biotechnologies Expands Executive Leadership Team to Support Development and Commercialization of Clinical Products, including immunoSEQ Dx


You May Also Like

Novavax Reports Second Quarter 2018 Financial Results

Novavax Delivers on Key Milestones Supporting its 2018 Objectives Company to Host Conference Call ...

TLC Files Registration Statement for Proposed Initial Public Offering

TAIPEI, Taiwan, Feb. 17, 2018 (GLOBE NEWSWIRE) -- Taiwan Liposome Company, Ltd. (4152.TWO) (TLC), ...